Sinopharm COVID-19 vaccine phase 3 trial begins in Abu Dhabi
DUBAI, July 16 (Reuters) - Chinese state-owned pharmaceutical company Sinopharm has begun phase 3 clinical trials of a COVID-19 vaccine in the emirate of Abu Dhabi, the Abu Dhabi government media office said on Thursday.
The human trial taking place in Abu Dhabi, part of the United Arab Emirates, is a partnership between Sinopharm's China National Biotec Group (CNBG), Abu Dhabi based artificial intelligence and cloud computing company Group 42 and the Abu Dhabi Department of Health.
(Reporting by Lisa Barrington; Editing by Alison Williams)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.